These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12141412)

  • 41. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.
    Sampaio EL; Pinheiro-Machado PG; Garcia R; Felipe CR; Park SI; Casarini DE; Moreira S; Franco MF; Tedesco-Silva H; Medina-Pestana JO
    Clin Transplant; 2008; 22(2):141-9. PubMed ID: 18339132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Drug-induced thrombotic thrombocytopenic purpura].
    Takahashi R
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():470-2. PubMed ID: 18074584
    [No Abstract]   [Full Text] [Related]  

  • 43. Sirolimus: not so sparing in the Spare-the-Nephron trial.
    Shamseddin MK; Gupta A
    Kidney Int; 2011 Jun; 79(12):1379; author reply 1379-80. PubMed ID: 21625260
    [No Abstract]   [Full Text] [Related]  

  • 44. [Toward an evidence-based immunosuppression].
    Pascual J
    Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
    [No Abstract]   [Full Text] [Related]  

  • 45. Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution.
    Toth CC; Burak K; Becker W
    Headache; 2005 Mar; 45(3):245-6. PubMed ID: 15836601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation.
    Paramesh AS; Grosskreutz C; Florman SS; Gondolesi GE; Sharma S; Kaufman SS; Fishbein TM
    Transplantation; 2004 Jan; 77(1):129-31. PubMed ID: 14724447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sirolimus: more cause for alarm?
    Agarwal PD; Lucey MR
    Liver Transpl; 2012 Sep; 18(9):1003-4. PubMed ID: 22639401
    [No Abstract]   [Full Text] [Related]  

  • 48. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA; Heizer KE
    Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inferior results with basis immunosuppression with sirolimus in kidney transplantation.
    van den Akker JM; Hené RJ; Hoitsma AJ
    Neth J Med; 2007 Jan; 65(1):23-8. PubMed ID: 17293636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases.
    Crew RJ; Radhakrishnan J; Cohen DJ; Stern L; Goldstein M; Hardy M; D'Agati VD; Markowitz GS
    Nephrol Dial Transplant; 2005 Jan; 20(1):203-9. PubMed ID: 15632351
    [No Abstract]   [Full Text] [Related]  

  • 51. Simultaneous PRES and TMA secondary to tacrolimus after allogeneic bone marrow transplant.
    Aruch DB; Renteria A
    Blood; 2015 Jun; 125(25):3963. PubMed ID: 26287041
    [No Abstract]   [Full Text] [Related]  

  • 52. Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome.
    Catalano G; De Simone P; Mazzoni A; Ghinolfi D; Coletti L; Filipponi F
    Transpl Int; 2014 Sep; 27(9):e84-6. PubMed ID: 24606320
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 55. Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506.
    Tezcan H; Zimmer W; Fenstermaker R; Herzig GP; Schriber J
    Bone Marrow Transplant; 1998 Jan; 21(1):105-9. PubMed ID: 9486505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tacrolimus-induced thrombotic microangiopathy: natural history of a severe, acute vasculopathy.
    Carson JM; Newman ED; Farber JL; Filippone EJ
    Clin Nephrol; 2012 Jan; 77(1):79-84. PubMed ID: 22185974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The ups and downs of sirolimus in kidney transplantation, and the importance of reporting negative findings.
    van Gelder T
    Neth J Med; 2007 Jan; 65(1):3-4. PubMed ID: 17293633
    [No Abstract]   [Full Text] [Related]  

  • 59. [Thrombotic thrombocytopenic purpura after circumcision].
    Schott F; Gross AJ; Netsch C; Segerer S
    Urologe A; 2017 Mar; 56(3):361-363. PubMed ID: 27272154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. End of the line for sirolimus in liver transplant recipients with hepatitis C virus?
    De Simone P; Saliba F; Fischer L
    Liver Transpl; 2013 Feb; 19(2):236-7. PubMed ID: 23225519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.